• Exchange: Tel Aviv
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Biocancell Ltd

+ Add to Watchlist

BICL:IT

214.80 ILs 0.40 0.19%

As of 03:33:40 ET on 09/02/2014.

Snapshot for Biocancell Ltd (BICL)

Open: 214.40 Day's Range: 214.80 - 214.80 Volume: 1,000
Previous Close: 214.40 52wk Range: 207.00 - 529.58 1-Yr Rtn: -51.68%

Stock Chart for BICL

No chart data available.
  • BICL:IT 214.80
  • 1D
  • 1M
  • 1Y
214.40
Interactive BICL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BICL

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. TA-100 -
Earnings Per Share (ttm) -0.8253
Est. EPS -
Est. PEG Ratio -
Market Cap (M ILS) 64.43
Shares Outstanding (M) 30.05
30 Day Average Volume 10,609
Price/Book (mrq) 3.9039
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/03/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BICL

  • Revenue
  • Net Income (M/ILS)
  • Profit Margin (%)

Company Profile & Key Executives for BICL

BioCancell Ltd. is a biopharmaceutical company that develops targeted cancer therapy treatments for numerous types of cancer. The treatment is based on utilizing a target gene, such as the H19 gene, an oncofetal gene expressed at high levels in over 40 types of human cancer tissues, while existing at a nearly undetectable level in the surrounding normal tissues.

Aharon SchwartzChairmanJonathan BurginChief Executive Officer
Avraham HochbergChief Scientist/Co-FounderMonique Ben-AmVP:Clinical Development
More Company Profile & Key Executives for BICL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil